A new report from business intelligence provider GBI Research – Global Viral
Infections Market to 2021 – states that the global viral infections market will grow
from $74 billion in 2014 to $117.6 billion by 2021, representing a compound annual growth rate of 6.8 per cent.
The expanding treatment population, which has resulted from improved treatment options and global initiatives to improve access to treatment for many people living with chronic debilitating viral infections such as HIV, will be a key driver of this growth.
Rising therapy costs resulting from the uptake of recently approved, highly-priced antiviral agents, as well as promising late-stage candidates which are expected to be priced highly, will also be a factor.
Analyst Fiona Chisholm said, ‘Some 1,848 pipeline products are specifically in
development for the treatment of viral infections, accounting for a sizeable proportion of
the infectious diseases pipeline. Among these products, HIV has the most at an active
stage of development, with 419, followed by influenza, Hepatitis C and Hepatitis B, with
333, 222 and 150 pipeline products, respectively.
‘Such strong activity is indicative of a high degree of commercial interest in viral
infections in general, and in these key indications in particular, which reflects the commercial success of currently marketed products such as Truvada, Atripla and Harvoni.
‘However, it should be noted that many products in the viral infections pipeline are being developed for multiple indications, including infectious diseases attributable to
non-viral micro-organisms.’
